Taiwan’s BRIM Biotechnology moves ahead with clinical trials for four new eye drugs. The company aims to address major eye conditions affecting millions globally. BRIM Biotechnology Chair Lin Chun revealed these advancements in a recent announcement. First, BRIM Biotechnology completed formulation and dosage optimization for BRM421, a dry eye treatment. The company submitted a human clinical trial application for BRM421 to the US FDA in May. Furthermore, they plan to file documents for a second Phase III trial later this year. This upcoming trial will refine dosage based on earlier study data.
Meanwhile, BRIM Biotechnology began clinical trials for BRM424, designed to treat neurotrophic keratitis. This degenerative corneal disease results from impaired sensory nerve function. Currently, two patients have enrolled in the US trial. Additionally, Brazil’s health authority approved the trial there, with patient enrollment set to start soon. Moreover, BRIM Biotechnology collaborated with the Industrial Technology Research Institute (ITRI) to improve BRM411, a glaucoma drug candidate. Glaucoma damages the optic nerve and is rapidly growing in Taiwan. The company applied to Taiwan’s FDA to begin human trials for BRM411.
According to General Manager Hsu Wen-chi, this drug may reduce side effects and attract interest from pharmaceutical companies. Besides glaucoma, BRIM Biotechnology is working on BRM412 for macular degeneration. This disease blurs central vision and can severely impact quality of life. The company enhanced BRM412’s formulation with ITRI’s help. They plan to submit a Phase II clinical trial application to the US FDA in the second half of the year. BRIM Biotechnology emphasizes that eye diseases affect many in Taiwan. According to the International Myopia Institute, over 73% of Taiwan’s population suffers from myopia. Severe myopia can cause cataracts, retinal detachment, macular degeneration, and even blindness.
Additionally, glaucoma diagnoses in Taiwan increased by 22% in the last five years. Currently, over 450,000 people have glaucoma. Macular degeneration affects about 10% of those aged 65 and older. BRIM Biotechnology pushes forward clinical trials for four new eye drugs to meet this growing health need. These efforts could bring better treatments to millions suffering from vision problems. As the company advances, it continues to focus on innovation and patient care.
